website templates

Next-Gen AAV Production

A research project for the therapeutics of tomorrow.

Gene therapy with Adeno-associated virus (AAV) vectors is on a steep rise, but efficient production of safe vectors remains a challenge. The ATIVAA project develops a next generation vector production platform - for the gene therapeutics of tomorrow.

Gene therapy is the substitution of a patients defective gene with a functional one. The therapeutic gene is delivered by a gene ferry, also called vector, which is often an engineered virus. The most prominent virus vector is the Adeno-associated virus (AAV). Two AAV-based therapeutics are currently approved for treatment and the clinical pipeline holds dozens more. However, a limited production capacity and production-based impurities lead to high therapy costs and impede a wide-spread application beyond rare genetic diseases. The ATIVAA project aims to address these problems with an innovative technology platform including up- and downstream processing of AAV vectors.

Funding

ATIVAA is a project of Bielefeld University. We recieve funding from the European Regional Development Fund (EFRE), the federal state of North Rhine-Westphalia (NRW) and Bielefeld University. Please use our form below to get in touch and join our growing community of collaborators and industry supporters!

Impressum 

Kathrin Teschner
Marco Radukic

Universität Bielefeld
Technische Fakultät
Raum E2-139
Universitätsstraße 25
33615 Bielefeld
 
Contact

Tel (office): +49-521-106-6322
E-Mail: marco.radukic@uni-bielefeld.de